BYL719 + AMG 479
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA Mutated Advanced Solid Tumors
Conditions
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Trial Timeline
Nov 27, 2012 → Jun 1, 2017
NCT ID
NCT01708161About BYL719 + AMG 479
BYL719 + AMG 479 is a phase 1/2 stage product being developed by Novartis for PIK3CA Mutated Advanced Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT01708161. Target conditions include PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01708161 | Phase 1/2 | Terminated |
Competing Products
13 competing products in PIK3CA Mutated Advanced Solid Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib + Placebo | Novartis | Phase 2 | 52 |
| alpelisib | Novartis | Pre-clinical | 23 |
| BYL719 + Fulvestrant | Novartis | Phase 1 | 33 |
| Inavolisib + Atezolizumab + Pembrolizumab | Roche | Phase 1 | 33 |
| CGT6297 | Cogent Biosciences | Phase 1 | 30 |
| RLY-5836 + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | Relay Therapeutics | Phase 1 | 28 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 47 |
| RLY-2608 + Capivasertib + Fulvestrant | Relay Therapeutics | Phase 3 | 72 |
| RLY-2608 + Fulvestrant + Palbociclib 125mg + Ribociclib 400mg + Ribociclib 600mg + PF-07220060 100mg + PF-07220060 300 mg | Relay Therapeutics | Phase 1 | 28 |